Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

Jw242 Mar. 16 at 2:16 PM

$IMUX gross but this is how we roll

0 · Reply

issaba Mar. 16 at 3:25 AM

$IMUX any announcements about Nasdaq compliance today ?

1 · Reply

michele1twits Mar. 16 at 3:21 AM

$IMUX

0 · Reply

Drerekcohert90 Mar. 15 at 2:17 PM

$IMUX $SLS $OCGN $IBRX I enjoyed this week , do you think next week IMUX will go up again . Thank you for your work!

1 · Reply

Nerdecus Mar. 14 at 8:35 AM

$IMUX https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/should-extended-european-patent-protection-for-vidofludimus/amp

0 · Reply

Algomist42 Mar. 13 at 9:48 PM

$IMUX WF?

1 · Reply

Whyasking Mar. 13 at 9:20 PM

$IMUX i am in

0 · Reply

Marcelkluetz Mar. 13 at 8:30 PM

$IMUX Great 2 weeks! back in compliance and new 52 week high (although Brief). Hold and let's see what next week brings.

1 · Reply

issaba Mar. 13 at 8:29 PM

$IMUX after hours

0 · Reply

1nceagain Mar. 13 at 8:14 PM

$IMUX I’m in!

0 · Reply

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 3, 2026, 6:30 AM EST - 13 days ago

Immunic to Participate in Investor Conferences in March

Feb 26, 2026, 6:30 AM EST - 18 days ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 17, 2026, 4:05 PM EST - 26 days ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 13, 2026, 11:25 AM EST - 4 weeks ago

Immunic Stock Jumps After Pricing $400 Million Private Placement

Feb 13, 2026, 6:30 AM EST - 4 weeks ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 4, 2026, 6:30 AM EST - 5 weeks ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Jan 7, 2026, 6:30 AM EST - 2 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Nov 26, 2025, 6:30 AM EST - 3 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 13, 2025, 6:30 AM EST - 4 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 4 months ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 5 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 6 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 6 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 4, 2025, 6:30 AM EDT - 6 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 7 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 9 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 9 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 10 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 10 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 10 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 10 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 10 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 11 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 11 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

Jw242 Mar. 16 at 2:16 PM

$IMUX gross but this is how we roll

0 · Reply

issaba Mar. 16 at 3:25 AM

$IMUX any announcements about Nasdaq compliance today ?

1 · Reply

michele1twits Mar. 16 at 3:21 AM

$IMUX

0 · Reply

Drerekcohert90 Mar. 15 at 2:17 PM

$IMUX $SLS $OCGN $IBRX I enjoyed this week , do you think next week IMUX will go up again . Thank you for your work!

1 · Reply

Nerdecus Mar. 14 at 8:35 AM

$IMUX https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/should-extended-european-patent-protection-for-vidofludimus/amp

0 · Reply

Algomist42 Mar. 13 at 9:48 PM

$IMUX WF?

1 · Reply

Whyasking Mar. 13 at 9:20 PM

$IMUX i am in

0 · Reply

Marcelkluetz Mar. 13 at 8:30 PM

$IMUX Great 2 weeks! back in compliance and new 52 week high (although Brief). Hold and let's see what next week brings.

1 · Reply

issaba Mar. 13 at 8:29 PM

$IMUX after hours

0 · Reply

1nceagain Mar. 13 at 8:14 PM

$IMUX I’m in!

0 · Reply

Teddy313 Mar. 13 at 7:04 PM

$IMUX IMO anyone selling will be very sorry, they didn't announce a RS they will vote on it in April and they can change there minds many times also they are loaded with cash and have compliance and most of all very powerful drugs in trials, come on all the stars are aligned. I can give you a list of dozens of low priced bios that people jumped ship and the stocks went through the roof. I'm one that left a few way to soon. I also had a lot of losers, my bet is IMUX will be my next big winner, RS or no RS as long as the drugs work.

2 · Reply

issaba Mar. 13 at 5:42 PM

$IMUX seems 1.17 is the floor.. good support at this level so far .. hope it will not be broken .. otherwise it might drop to 1.07 ..

3 · Reply

issaba Mar. 13 at 4:46 PM

$IMUX watching 1.17 support level

1 · Reply

ErnieWorthing84 Mar. 13 at 3:56 PM

$IMUX Great work!

0 · Reply

takingstock73 Mar. 13 at 3:24 PM

$IMUX for those who thought wish I had more here is your chance

0 · Reply

WintersJohn Mar. 13 at 3:17 PM

$IMUX Missed the opportunity to sell at $1.50... oh well! Back down we go! Reverse coming next!

4 · Reply

ErnieWorthing84 Mar. 13 at 3:02 PM

$IMUX Healthy, like a colon cleanse

2 · Reply

Trader1141 Mar. 13 at 2:46 PM

$AIFF ADHD news always hot and tend to blow up $DRUG $AMTX $SOS $IMUX

0 · Reply

algo888 Mar. 13 at 2:07 PM

$IMUX April voting for the R/S reason its down..

1 · Reply

MichToss99 Mar. 13 at 12:38 PM

$SLS $IBRX $OCGN $ABOS $IMUX Great work, Jack. What I have witnessed so far, you are putting a lot of effort into it!

0 · Reply

takingstock73 Mar. 13 at 12:03 PM

$IMUX let's make a real run to $2 today

1 · Reply

jacksparo Mar. 13 at 11:53 AM

$SLS $IBRX $OCGN $ABOS $IMUX I will be watching and taking notes to share updates on some small/micro cap biotech! Let us see what today will bring! All the live updates I share in my Live Telegram Biotech group! We need a green day today!

5 · Reply

Market Cap	152.64M
Revenue (ttm)	0.00
Net Income (ttm)	-97.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,055,800
Avg Vol	3,831,880
Day's Range	N/A - N/A
Shares Out	130.47M
Stochastic %K	27%
Beta	1.46
Analysts	Strong Sell
Price Target	$4.75